Seralutinib
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 4, 2017 (NCT03473236)
Timeline
Indications
Mechanism of action
PDGFRA inhibitor
Platelet-derived growth factor receptor inhibitor
- Stem cell growth factor receptorINHIBITOR
Stem cell growth factor receptor inhibitor
Macrophage colony stimulating factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC- Mol. weight
- 469.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650333 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07181382 | Phase 3 | Dec 31, 2025 | Chiesi, Gossamer Bio Inc. |
| NCT06274801 | Phase 3 | Sep 3, 2024 | Gossamer Bio Inc. |
| NCT05934526 | Phase 3 | Sep 30, 2023 | Gossamer Bio Inc. |
| NCT06423261 | Phase 1 | Aug 24, 2023 | Government of China |
| NCT04816604 | Phase 2 | Apr 5, 2021 | Gossamer Bio Inc. |
| NCT04456998 | Phase 2 | Dec 14, 2020 | Gossamer Bio Inc. |
| NCT03926793 | Phase 1 | Jun 30, 2019 | Gossamer Bio Inc. |
| NCT03473236 | Phase 1 | Sep 4, 2017 | Gossamer Bio Inc., Pulmokine Inc., Worldwide Clinical Trials |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gossamer Bio Inc. | For profit | 7 | 7 | 3 | 2017 |
| Chiesi | For profit | 1 | 0 | 1 | 2025 |
| Government of China | Government | 1 | 1 | 1 | 2023 |
| Pulmokine Inc. | For profit | 1 | 0 | 1 | 2017 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1